Short Interest in OmniAb, Inc. (NASDAQ:OABIW) Declines By 42.4%

OmniAb, Inc. (NASDAQ:OABIW) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 10,640 shares, a decrease of 42.4% from the August 15th total of 18,488 shares. Based on an average daily trading volume, of 46,171 shares, the short-interest ratio is presently 0.2 days.

OmniAb Stock Performance

OABIW traded down $0.15 during trading on Wednesday, hitting $0.22. The stock had a trading volume of 1,790 shares, compared to its average volume of 17,180. OmniAb has a 12 month low of $0.04 and a 12 month high of $0.42. The company has a 50 day simple moving average of $0.16 and a 200-day simple moving average of $0.12.

OmniAb Company Profile

OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.

At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.